Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 2/20 | 0.40 |
| ▸ | PDE8B | O95263 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18497645 | 1.00 | ATM (0.44) | ATMHSD17B10ALDH1A1HRH3SMN1; SMN2 | |
| SCHEMBL1648263 | 0.91 | ATM (0.41) | ATMHSD17B10ALDH1A1SMN1; SMN2METAP2 | |
| SCHEMBL1401178 | 0.85 | HSD17B10 (0.49) | ATMHSD17B10ALDH1A1SMN1; SMN2PDE8B | |
| SCHEMBL20522096 | 0.85 | HSD17B10 (0.49) | ATMHSD17B10ALDH1A1SMN1; SMN2PDE8B | |
| SCHEMBL6899788 | 0.83 | HSD17B10 (0.49) | ATMHSD17B10ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL1467517 | 0.83 | HSD17B10 (0.49) | ATMHSD17B10ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3576321 | 0.83 | HSD17B10 (0.49) | ATMHSD17B10ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL21216318 | 0.82 | KDM1A (0.42) | ATMHSD17B10ALDH1A1SMN1; SMN2PDE8B | |
| SCHEMBL29739 | 0.82 | HSD17B10 (0.48) | ATMHSD17B10ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL398772 | 0.82 | HSD17B10 (0.48) | ATMHSD17B10ALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190084968-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190084969-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10023561-B2 | Fumagillol heterocyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3334728-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20170342058-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9682965-B2 | Fumagillol heterocyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170066749-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-03-09 | — | — | US | disclosed |
| WO-2017027684-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084969-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | ATM 1870/4885HSD17B10 413/4885ALDH1A1 450/4885 |
| US-20170066749-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | ATM 1870/4885HSD17B10 413/4885ALDH1A1 450/4885 |
| US-20170342058-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | ATM 1870/4885HSD17B10 413/4885ALDH1A1 450/4885 |
| US-20190084968-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | ATM 1870/4885HSD17B10 413/4885ALDH1A1 450/4885 |
| US-10023561-B2 | Fumagillol heterocyclic compounds and methods of making and using same | METAP2, FAP, FOLH1 | ATM 1870/4885HSD17B10 413/4885ALDH1A1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.